| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation expense | 48,376 |
| Net loss | -50,532 |
| Other non-cash adjustments | -1,963 |
| Prepaid expenses and other current assets | 1,822 |
| Other liabilities | 5,477 |
| Other non-current assets | 603 |
| Inventories | 1,861 |
| Accrued compensation | -4,692 |
| Accrued expenses | 3,434 |
| Accounts receivable, net | 15,172 |
| Accounts payable | 9,616 |
| Impairment of long-lived assets | 0 |
| Gain on sale of business | 48,847 |
| Depreciation and amortization expense | 18,849 |
| Net cash used in operating activities | -35,814 |
| Proceeds from maturity of investments | 28,975 |
| Proceeds from sale of business | 2,500 |
| Purchases of property and equipment | 15,577 |
| Purchases of investments | 28,257 |
| Net cash used in investing activities | -12,359 |
| Proceeds from exercise of stock options | 5,551 |
| Proceeds from the issuance of liability related to sale of future revenue | 15,000 |
| Proceeds from issuance of common stock under employee stock purchase plan | 2,429 |
| Repurchases of common stock for income tax withholding | 14 |
| Net cash provided by financing activities | 22,966 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -20 |
| Net decrease in cash, cash equivalents, and restricted cash | -25,227 |
Twist Bioscience Corp (TWST)
Twist Bioscience Corp (TWST)